Sustained Therapeutics is a clinical stage company developing a drug delivery platform initially focused on non-opioid pain medication but extendable to other APIs including significant oncology indications. This technology aims to transform drugs into novel locally injectable medications providing new treatments for pain, inflammatory diseases and cancer. Our pain medication is designed to prolong pain control for one month or longer, allowing treatment of chronic and acute pain. We have two Phase II trials underway, one in acute and the other in chronic pain. We plan to complete our acute pain trial in late 2024 and our chronic pain trial in early 2025. In addition we are developing our second product, which targets oncology. Our first indication is upper tract urothelial carcinoma (UTUC), an orphan disease, but we believe that the product could be extendable into other cancer indications as well. We have just initiated the pivotal Phase II/III trial of this product in UTUC.